FR2762841B1 - Diazepino-indolones inhibitrices de phosphodiesterases iv - Google Patents

Diazepino-indolones inhibitrices de phosphodiesterases iv

Info

Publication number
FR2762841B1
FR2762841B1 FR9705422A FR9705422A FR2762841B1 FR 2762841 B1 FR2762841 B1 FR 2762841B1 FR 9705422 A FR9705422 A FR 9705422A FR 9705422 A FR9705422 A FR 9705422A FR 2762841 B1 FR2762841 B1 FR 2762841B1
Authority
FR
France
Prior art keywords
formula
compounds
indolones
diazepino
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9705422A
Other languages
English (en)
French (fr)
Other versions
FR2762841A1 (fr
Inventor
Yves Pascal
Catherine Burnouf
Bernard Gaudilliere
Alain Calvet
Adrian Payne
Svein G Dahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut de Recherche Jouveinal
Original Assignee
Institut de Recherche Jouveinal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut de Recherche Jouveinal filed Critical Institut de Recherche Jouveinal
Priority to FR9705422A priority Critical patent/FR2762841B1/fr
Priority to HR980231A priority patent/HRP980231B1/xx
Priority to DE69811360T priority patent/DE69811360T2/de
Priority to DK98925598T priority patent/DK0980374T3/da
Priority to AU77652/98A priority patent/AU729495B2/en
Priority to BR9809429-7A priority patent/BR9809429A/pt
Priority to KR1019997010008A priority patent/KR20010020386A/ko
Priority to AT98925598T priority patent/ATE232534T1/de
Priority to ES98925598T priority patent/ES2190083T3/es
Priority to ZA9803704A priority patent/ZA983704B/xx
Priority to MXPA99006979A priority patent/MXPA99006979A/es
Priority to JP54662498A priority patent/JP2001522367A/ja
Priority to US09/380,883 priority patent/US6239130B1/en
Priority to NZ337589A priority patent/NZ337589A/xx
Priority to CA002278217A priority patent/CA2278217A1/en
Priority to PCT/EP1998/002827 priority patent/WO1998049169A1/en
Priority to EP98925598A priority patent/EP0980374B1/en
Publication of FR2762841A1 publication Critical patent/FR2762841A1/fr
Application granted granted Critical
Publication of FR2762841B1 publication Critical patent/FR2762841B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FR9705422A 1997-04-30 1997-04-30 Diazepino-indolones inhibitrices de phosphodiesterases iv Expired - Fee Related FR2762841B1 (fr)

Priority Applications (17)

Application Number Priority Date Filing Date Title
FR9705422A FR2762841B1 (fr) 1997-04-30 1997-04-30 Diazepino-indolones inhibitrices de phosphodiesterases iv
HR980231A HRP980231B1 (en) 1997-04-30 1998-04-29 Phosphodiesterase 4 - inhibiting diazepinoindolones
JP54662498A JP2001522367A (ja) 1997-04-30 1998-04-30 ホスホジエステラーゼ4−阻害ジアゼピノインドロン
AU77652/98A AU729495B2 (en) 1997-04-30 1998-04-30 Phosphodiesterase 4-inhibiting diazepinoindolones
BR9809429-7A BR9809429A (pt) 1997-04-30 1998-04-30 Diazepinoindolonas inibidoras de fosfodiesterase 4
KR1019997010008A KR20010020386A (ko) 1997-04-30 1998-04-30 포스포디에스테라제 4를 억제하는 디아제피노인돌론
AT98925598T ATE232534T1 (de) 1997-04-30 1998-04-30 Diazepinoindolone als phophodiesterase 4 inhibitoren
ES98925598T ES2190083T3 (es) 1997-04-30 1998-04-30 Diazepinoindoles inhibidores de fosfodiesterasa 4'.
DE69811360T DE69811360T2 (de) 1997-04-30 1998-04-30 Diazepinoindolone als phophodiesterase 4 inhibitoren
MXPA99006979A MXPA99006979A (es) 1997-04-30 1998-04-30 Diazepinoindolonas que inhiben la fosfodiesterasa4.
DK98925598T DK0980374T3 (da) 1997-04-30 1998-04-30 Phosphodiesterase 4-inhiberende diazepinoindoloner.
US09/380,883 US6239130B1 (en) 1997-04-30 1998-04-30 Phosphodiesterase 4-inhibiting diazepinoindolones
NZ337589A NZ337589A (en) 1997-04-30 1998-04-30 [1,4]diazepino[6,7,1-hi]indol-4-ones and there use in treating inflammatory diseases
CA002278217A CA2278217A1 (en) 1997-04-30 1998-04-30 Phosphodiesterase 4-inhibiting diazepinoindolones
PCT/EP1998/002827 WO1998049169A1 (en) 1997-04-30 1998-04-30 Phosphodiesterase 4-inhibiting diazepinoindolones
EP98925598A EP0980374B1 (en) 1997-04-30 1998-04-30 Phosphodiesterase 4-inhibiting diazepinoindolones
ZA9803704A ZA983704B (en) 1997-04-30 1998-04-30 Phosphodiesterase 4-inhibiting diazepinoindolones.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9705422A FR2762841B1 (fr) 1997-04-30 1997-04-30 Diazepino-indolones inhibitrices de phosphodiesterases iv

Publications (2)

Publication Number Publication Date
FR2762841A1 FR2762841A1 (fr) 1998-11-06
FR2762841B1 true FR2762841B1 (fr) 1999-07-02

Family

ID=9506517

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9705422A Expired - Fee Related FR2762841B1 (fr) 1997-04-30 1997-04-30 Diazepino-indolones inhibitrices de phosphodiesterases iv

Country Status (17)

Country Link
US (1) US6239130B1 (OSRAM)
EP (1) EP0980374B1 (OSRAM)
JP (1) JP2001522367A (OSRAM)
KR (1) KR20010020386A (OSRAM)
AT (1) ATE232534T1 (OSRAM)
AU (1) AU729495B2 (OSRAM)
BR (1) BR9809429A (OSRAM)
CA (1) CA2278217A1 (OSRAM)
DE (1) DE69811360T2 (OSRAM)
DK (1) DK0980374T3 (OSRAM)
ES (1) ES2190083T3 (OSRAM)
FR (1) FR2762841B1 (OSRAM)
HR (1) HRP980231B1 (OSRAM)
MX (1) MXPA99006979A (OSRAM)
NZ (1) NZ337589A (OSRAM)
WO (1) WO1998049169A1 (OSRAM)
ZA (1) ZA983704B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2795731B1 (fr) * 1999-07-02 2001-09-07 Warner Lambert Co PROCEDE DE PREPARATION DE [1,4] DIAZEPINO [6,7,1-hi] INDOL-4-ONES SUBSTITUEES
CA2401697A1 (en) * 2000-03-03 2001-09-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
EP1161949A1 (en) 2000-06-09 2001-12-12 Warner-Lambert Company Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
WO2002094321A1 (en) * 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions for promoting healing of bone fracture
WO2002094320A1 (en) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Therapeutic compositions for repairing chondropathy
AU2002317377A1 (en) * 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
US20090042951A1 (en) * 2004-02-20 2009-02-12 Robert Danziger Blood Pressure Reduction in Salt-Sensitive Hypertension
WO2005102317A1 (en) * 2004-04-23 2005-11-03 Celgene Corporation Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
BRPI0610498A2 (pt) * 2005-04-19 2010-06-22 Nycomed Gmbh uso de roflumilast,composição farmacêutica, produto de combinação e kit para o tratamento de hipertensão pulmonar
CA2663436A1 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
RU2009141592A (ru) * 2007-04-11 2011-05-20 Алькон Рисерч, Лтд. (Us) ПРИМЕНЕНИЕ ИНГИБИТОРА TNFα В СОЧЕТАНИИ С АНТИГИСТАМИННЫМ СРЕДСТВОМ ДЛЯ ЛЕЧЕНИЯ АЛЛЕРГИЧЕСКОГО РИНИТА И АЛЛЕРГИЧЕСКОГО КОНЪЮНКТИВИТА
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
US20090005381A1 (en) * 2007-06-26 2009-01-01 Philip Manton Brown Methods of treating serotonin-mediated diseases and disorders
RU2012117141A (ru) * 2009-10-01 2013-11-10 Алькон Рисерч, Лтд. Композиции олопатадина и способы их применения
US12472241B2 (en) 2018-12-28 2025-11-18 Regeneron Pharmaceuticals, Inc. Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2725719B1 (fr) * 1994-10-14 1996-12-06 Jouveinal Inst Rech Diazepino-indoles inhibiteurs de phosphodiesterases iv

Also Published As

Publication number Publication date
NZ337589A (en) 2000-10-27
EP0980374A1 (en) 2000-02-23
ATE232534T1 (de) 2003-02-15
HRP980231B1 (en) 2002-06-30
AU7765298A (en) 1998-11-24
JP2001522367A (ja) 2001-11-13
FR2762841A1 (fr) 1998-11-06
AU729495B2 (en) 2001-02-01
DK0980374T3 (da) 2003-05-05
US6239130B1 (en) 2001-05-29
MXPA99006979A (es) 2005-04-19
CA2278217A1 (en) 1998-11-05
BR9809429A (pt) 2000-06-13
HRP980231A2 (en) 2000-04-30
ES2190083T3 (es) 2003-07-16
DE69811360D1 (de) 2003-03-20
DE69811360T2 (de) 2003-10-09
WO1998049169A1 (en) 1998-11-05
ZA983704B (en) 1999-10-25
KR20010020386A (ko) 2001-03-15
EP0980374B1 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
ES2190083T3 (es) Diazepinoindoles inhibidores de fosfodiesterasa 4'.
FI945557A0 (fi) Isoksatsoliiniyhdisteet tulehduksenvastaisina aineina
ATE187447T1 (de) 3-phenyl-2-isoxazoline derivate als entzündugshemmende mittel
AU2721402A (en) Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
AU2019502A (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
BG104138A (en) 2-aminopyridines containing substituents with condensed rings as nos inhibitors
ZA9810735B (en) Novel benzenesulfonamide inhibitors of pde-iv and their therapeutic use
IL163629A0 (en) Glutaminyl derivatives and pharmaceutical compositions containing the same
BG102872A (en) 6-phenylpyridyl-3-amine derivatives
CA2400447A1 (en) Kinase inhibitors
DE69824037D1 (de) Beta-alanin-derivate als zell-adhäsions-inhibitoren
DE60005355D1 (de) Bradikinin b1 rezeptor antagonisten
DK0873340T3 (da) Heterocyklisk substituerede cyclopentanforbindelser
WO2004054501A3 (en) Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
WO2003041643A3 (en) Hsp90-inhibiting zearalanol compounds and methods of producing and using same
DE69905476D1 (en) Phosphonsaürederivate als ptp-1b-inhibitoren
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
AP2000001992A0 (en) Succinamide inhibitors of inteleukin-1B converting enzyme.
WO2002051848A3 (de) Sulfamidothienopyrimidine zur verwendung als phosphodiesterase v-hemmer
BG104292A (en) Methods and compositions for the treatment of rheumatoid arthritis
NO20026246D0 (no) 2-aminoalkyl-tieno[2,3-d]pyrimidiner

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20061230